The investigational treatment is called "Synchronized Transcranial Magnetic Stimulation" (abbreviated "sTMS"). sTMS therapy is delivered by a device in the research clinic to patients who have Major Depression. The sTMS device (manufactured by NeoSync, Inc.) generates an alternating magnetic field close to a patient's head while they are awake and alert, with synchronization of the magnetic fields delivered to the patient's own brainwave patterns. Pilot studies have shown sTMS therapy improved symptoms in patients with Major Depressive Disorder and minimal side effects were reported. Study participants will be randomly assigned to receive either active sTMS of a series of "sham" (placebo) treatment sessions, for a course of 30 treatments given over a period of 6 weeks. Following completion of all treatment and evaluation visits, patients may be eligible to receive 4 weeks of active sTMS treatment.